What else should be considered for your patients with CKD associated with T2D?

Mineralocorticoid receptor is1:

  • Activated by aldosterone and cortisol

 

Overactivation of the mineralocorticoid receptor is1:

  • Thought to contribute to inflammation and fibrosis

Mineralocorticoid receptor is1:

  • Activated by aldosterone and cortisol

 

Overactivation of the mineralocorticoid receptor is1:

  • Thought to contribute to inflammation and fibrosis
info icon

Inflammation and fibrosis can contribute to permanent structural damage in your patients' kidneys2,3

In adult patients with CKD associated with T2D

KERENDIA is the first and only selective mineralocorticoid receptor antagonist with a nonsteroidal structure1

KERENDIA1:

 

  • In tissues such as kidney, heart, and blood vessels, blocks:
    • Mineralocorticoid receptor overactivation
    • Mineralocorticoid receptor mediated sodium reabsorption
  • Has a high potency and selectivity for the mineralocorticoid receptor
  • Has no relevant affinity for androgen, progesterone, estrogen, and glucocorticoid receptors

KERENDIA1:

 

  • In tissues such as kidney, heart, and blood vessels, blocks:
    • Mineralocorticoid receptor overactivation
    • Mineralocorticoid receptor‐mediated sodium reabsorption
  • Has a high potency and selectivity for the mineralocorticoid receptor
  • Has no relevant affinity for androgen, progesterone, estrogen, and glucocorticoid receptors
info icon

KERENDIA blocks mineralocorticoid receptor overactivation, which is thought to contribute to inflammation and fibrosis1

Learn about safety and dosing

CKD=chronic kidney disease; MR=mineralocorticoid receptor; T2D=type 2 diabetes.

IMPORTANT SAFETY INFORMATION AND INDICATION

INDICATION:

  • KERENDIA is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D)

CONTRAINDICATIONS:

  • Concomitant use with strong CYP3A4 inhibitors
  • Patients with adrenal insufficiency

WARNINGS AND PRECAUTIONS:

  • Hyperkalemia: KERENDIA can cause hyperkalemia. The risk for developing hyperkalemia increases with decreasing kidney function and is greater in patients with higher baseline potassium levels or other risk factors for hyperkalemia. Measure serum potassium and eGFR in all patients before initiation of treatment with KERENDIA and dose accordingly. Do not initiate KERENDIA if serum potassium is >5.0 mEq/L

     

    Measure serum potassium periodically during treatment with KERENDIA and adjust dose accordingly. More frequent monitoring may be necessary for patients at risk for hyperkalemia, including those on concomitant medications that impair potassium excretion or increase serum potassium

MOST COMMON ADVERSE REACTIONS:

  • Adverse reactions reported in ≥1% of patients on KERENDIA and more frequently than placebo: hyperkalemia (18.3% vs. 9%), hypotension (4.8% vs. 3.4%), and hyponatremia (1.4% vs. 0.7%)

DRUG INTERACTIONS:

  • Strong CYP3A4 Inhibitors: Concomitant use of KERENDIA with strong CYP3A4 inhibitors is contraindicated. Avoid concomitant intake of grapefruit or grapefruit juice
  • Moderate and Weak CYP3A4 Inhibitors: Monitor serum potassium during drug initiation or dosage adjustment of either KERENDIA or the moderate or weak CYP3A4 inhibitor and adjust KERENDIA dosage as appropriate
  • Strong and Moderate CYP3A4 Inducers: Avoid concomitant use of KERENDIA with strong or moderate CYP3A4 inducers

USE IN SPECIFIC POPULATIONS:

  • Lactation: Avoid breastfeeding during treatment with KERENDIA and for 1 day after treatment
  • Hepatic Impairment: Avoid use of KERENDIA in patients with severe hepatic impairment (Child Pugh C) and consider additional serum potassium monitoring with moderate hepatic impairment (Child Pugh B)

INDICATION:

  • KERENDIA is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D)

Please read the Prescribing Information for KERENDIA.

References:

  • KERENDIA (finerenone) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc.; July 2021. Return to content
  • Thomas MC, et al. Nat Rev Dis Primers. 2015;1. doi: 10.1038/nrdp.2015.18. Return to content
  • Alicic RZ, et al. Clin J Am Soc Nephrol. 2017;12(12):2032-2045. Return to content